Document:

Blueprint

  Exhibit 10.4

CONFIDENTIAL TREATMENT REQUESTED

 

The confidential portions of this exhibit have been delivered
separately to the Securities and Exchange Commission pursuant to a
confidential application for confidential treatment in accordance
with Rule 24b-2 under the Securities Exchange Act of 1934, as
amended.

 

REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN
[***].

 

 

TRADEMARK
LICENSE AGREEMENT – AMENDMENT 2

 

THIS AMENDMENT is made on August 8, 2016
between:

 

(1) 

MOTOROLA MOBILITY
LLC., a Delaware corporation, having its principal its principal
office at 222 West Merchandise Mart Plaza, Chicago, IL 60654 , USA
(“Motorola”); and

 

(2) 

ZOOM TELEPHONICS,
INC., a Delaware Corporation having its principal office at 207
South Street, Boston MA 02111 USA, and its wholly owned subsidiary
MTRLC LLC, a Delaware limited liability company, having an office
at 160 Greentree Drive, Suite 101, Dover, Delaware 19904 USA
(“Licensee”).

 

WHEREAS,
Licensee and Motorola entered into a Licensee Agreement for cable
modems and gateways, effective January 1, 2016 (the
“Agreement”), and;

 

WHEREAS,
the Parties intend to amend the Agreement upon the terms and
conditions contained herein.

 

NOW,
THEREFORE, in consideration of the promises and covenants set forth
herein, the adequacy of which is hereby acknowledged, the Parties
hereto agree as follows:

 

1.

Exhibit A to the
Agreement shall be deleted in its entirety and replaced with the
Attached Exhibit A.

 

2.

The following shall
be added as a new Section 6.5

 

“The Products
shall carry a unique identifier (e.g., a unique serial number or
date code) to distinguish them from other products offered,
provided or sold by Licensee, Licensor and/or third-party
licensees. Such unique identifiers shall be sufficient for Licensee
to fully and accurately track each Product through the distribution
chain to the end consumer, as well as in connection with all
post-sales, return, repair, customer support and other services
relating to the Products or the Manufacturer’s Warranty (as
defined herein). Licensee shall at its sole expense ensure that
Licensee as well as all Approved Manufacturers have implemented
systems sufficient to enable such tracking and to facilitate all
reporting to Licensor regarding the Products required under this
Agreement. Licensee shall at its sole expense promptly and fully
comply with all anti-counterfeiting programs and initiatives
relating to the Products as directed by Licensor in its sole
discretion. Licensee acknowledges and agrees that at a minimum, if
an Approved Manufacturer also sells or distributes the Product on
Licensee’s behalf, that such Approved Manufacturer shall
affix a serialized anti-counterfeiting label to such Product, and
comply with the Motorola’s anti-counterfeiting
program.”

 

 

 

 

3.

The terms of the
Agreement shall remain in full force and effect except as
specifically amended herein. Defined terms, not otherwise defined
herein, shall have the same meaning as set forth in the
Agreement.

 

4.

This Amendment is
binding on the respective parties, their permitted successors in
interest, assignees, executors, administrators and heirs of the
parties.

 

5.

This Amendment may
be executed in one or more counterparts, and by the different
parties hereto in separate counterparts, each of which when
executed will be deemed to be an original but all of which taken
together will constitute one and the same agreement. This Amendment
may be executed and delivered by electronic mail (email) or
facsimile copies, each of which shall be deemed an original, but
all of which together shall constitute one and the same
instrument.

 

IN
WITNESS WHEREOF, the Parties haves caused this Amendment to be
executed by their duly authorized representatives on the dates
indicated below:

 

	

MOTOROLA
MOBILITY LLC.

	

ZOOM
TELEPHONICS, INC

 

	

 

By: /s/
Nadim Halabi_________________

           
Nadim
Halabi

	

 

BY: /s/
Frank Manning________________

            
Frank
Manning

	

 

Title:
Director, Trademark Licensing

	

 

Title:
President and CEO

 

	

 

Date:
August 16, 2016

	

 

Date:
August 12, 2016

 

 

 

 

EXHIBIT A

(Revised by Amendment #2)

 

License between Motorola and Zoom Telephonics, Inc.

 

Products:

1)

Broadband cable
modems, including standalone cable
modems; cable modems containing routers; and cable set-top boxes
containing cable modems.

2)

Routers, including
wireless (Wi-Fi), wired, and routers with built-in cellular
modems.

3)

Wi-Fi range
extenders.

4)

Home powerline
network adaptors (i.e. a device that extends wired or wireless
broadband connections to an AC outlet using the existing electrical
wiring).

5)

Wireless access
points (i.e. networking
hardware devices that
allow a Wi-Fi enabled device to
connect to a wired network). 

 

All of the foregoing shall be consumer-grade, and designed for and
intended for use by consumers. Broadband cable Modems may or may
not include voice, Packetcable, or EMTA capability, provided such
modems shall not be marketed or bundled with wireless, corded or
cordless phones, or otherwise as an end-to-end solution for making
phone calls.

 

Territory: Worldwide

 

Authorized Channels:

1)

Retail and cable
operator stores, including department stores (e.g. Sears), chain
consumer electronics stores (e.g. Best Buy), cable operator stores
(e.g. Comcast), etailers (e.g. Amazon), warehouse clubs (e.g.
Costco), Shop-at-home TV channels (e.g. QVC) and general
merchandise stores (e.g. Walmart), but specifically excluding deep
discount retailers, and liquidators (e.g. Big Lots).

2)

Service providers
(e.g. Comcast)

3)

Distributors to
these channels (e.g. Ingram).

 

Royalty Rate:

 

●

[*.*]% of Net Sales
for Products sold for use in the [*****], [*****], [*****],
[*****], [*****], [*****], [*****], and the countries,

territories and
special sovereign areas of [*****], including
[*************************************
*********************

************************************************************************************************************

************************************************************************************************************

***********************************************************************************************************].

 

●

[*]% of Net Sales
for Products sold for use in the rest of the World.

 

 

 

 

Minimum Royalty: $17 million, broken down as
follows:

 

●

2016:
$2M

●

2017:
$3M

●

2018:
$3.5M

●

2019:
$4.0M

●

2020:
$4.5M

 

Set-Up Fee: $[******], paid January 2016.

 

Term: January 1, 2016 – Dec 31, 2020

 

Sales Year: Jan. to December 31.SECOND
AMENDMENT TO WARRANT

 

THIS SECOND AMENDMENT (“Second Amendment”)
effective as of November 30, 2016, hereby amends the COMMON STOCK PURCHASE WARRANTS (the “Warrants”) dated
the 4th day of May 2016, is entered into by and between Vitality Biopharma, Inc., a Nevada
corporation (the “Company”), and the holders of all of the Warrants who have executed this Second Amendment
below (the “Holders”).

 

WHEREAS,
the Company issued the Warrants held by the Holders; and

 

WHEREAS,
the Company and the Holders desire to amend the terms of the Warrants as provided herein to change the Beneficial Ownership Limitation
from 9.99% to 4.99%.

 

NOW,
THEREFORE, in consideration of the premises contained herein and other good and valuable consideration, the receipt and legal
sufficiency of which are hereby acknowledged, the Company and the Holders hereby agree as follows:

 

	 	1.	Section
    2(e) of the Warrant is hereby replaced in its entirety by the following:
	 	 	 
	 	2.	 
	 	 	 

e)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of
shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock
issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of
shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially
owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any
other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on
conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall
be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and
of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a
Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic
or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company,
may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership
Limitation in no event exceeds 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to
the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e)
shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day
after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which
may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to
a successor holder of this Warrant.

 

	 	3.	All
    capitalized terms not defined herein have the same meaning as in the Warrants.
	 	 	 
	 	4.	Any
    and all provisions of the Warrants not expressly modified herby shall remain in full force and effect. 

 

    	 		 

    	 		 

    

 

IN
WITNESS WHEREOF, each of the parties hereto has caused this Second Amendment to be executed by its duly authorized officer as
of the date first written above.

 

	Vitality
    Biopharma, Inc.	 
	 	 	 
	By:
    	/s/
    Robert Brooke	 
	Name:
    	Robert
    Brooke 	 
	Title:
    	CEO	 
	 	 	 
	Quezon
    Group LLC	 
	 	 	 
	By:
    	/s/
    Virgilio Santana	 
	Name:
    	Virgilio
    Santana	 
	Title:
	Director	 
	 	 	 
	Trius
    Holding Limited	 
	 	 	 
	By:
    	/s/
    Jordan Wolsey	 
	Name:
    	Jordan
    Wolsey	 
	 	 	 
	Gotama
    Capital SA	 
	 	 	 
	By:
    	/s/
    Fedir Nikolayev	 
	Name:
	Fedir
    Nikolayev	 
	Title:
    	President	 
	 	 	 
	Hampton
    Partners Inc.	 
	 	 	 
	By:
    	/s/
    Scott Cabianca	 
	Name:
	Scott
    Cabianca	 
	Title:
    	Director	 
	 	 	 
	Corby
    Ventures Inc.	 
	 	 	 
	By:
    	/s/
    Richard Smith	 
	Name:
    	Richard
    Smith	 
	 	 	 
	Santo
    Torres LLC	 
	 	 	 
	By:
    	/s/
    Miguel Robles	 
	Name:
    	Miguel
    Robles	 
	Title:
    	Director	 
	 	 	 
	Morris
    Capital Inc.	 
	 	 	 
	By:
    	/s/
    Rob Harris	 
	Name:
    	Rob
    Harris	 
	Title:
	Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]